Product Description
Insulin aspart is a short-acting, manmade version of human insulin. Insulin aspart works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. (Sourced from: https://medlineplus.gov/druginfo/meds/a605013.html)
Mechanisms of Action: INSR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 21
Highest Development Phases
Phase 3: General Diabetes|Healthy Volunteers|Pregnancy Outcomes|Type 1 Diabetes|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 22011-DM-301 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2023-12-01 |
63% |
| 22011-DM-301 | P3 |
Not yet recruiting |
Type 2 Diabetes |
2023-12-01 |
63% |
| In-FI | P3 |
Completed |
Type 2 Diabetes |
2023-05-27 |
|
| API-I004-CL-B | P3 |
Completed |
Healthy Volunteers |
2023-01-29 |
55% |
| CTR20220854 | P1 |
Completed |
Healthy Volunteers|General Diabetes |
2022-10-24 |